论文部分内容阅读
目的:观察和评价吉西他滨(GEM)联合长春瑞滨(NVB)治疗晚期非小细胞肺癌(NSCLC)的疗效和毒性。方法:GEM1 000mg/m2 加生理盐水(NS)100ml, 30分钟内滴注,第1、8天;NVB25mg/m2 加NS70ml快速静脉推注,第1、8天。21天为1个周期,至少治疗2个周期。结果: 21例NSCLC患者, 10例完成2个周期, 6例3个周期, 5例4个周期,共治疗58个周期。CR1例,PR9例,SD9例,PD2例,总有效率(CR+PR)为47 6%;初治8例,复治13例,有效率分别为62 5% ( 5 /8例)和38 5% (5 /13例) (P<0 05);鳞癌8例,腺癌13例,有效率分别为62 5% (5 /8例)和38 5% (5 /13例) (P<0 05)。中位生存期(MST)11 5个月, 1年生存率为42 0%。毒性反应主要有白细胞减少、血小板下降、血红蛋白降低;白细胞减少Ⅲ~Ⅳ度者占28.6% (6 /21),血小板下降和血红蛋白下降Ⅲ~Ⅳ度分别为14 3% (3 /21)和4.8% (1 /21)。结论:吉西他滨联合长春瑞滨治疗晚期非小细胞肺癌具有较好的疗效,毒性反应可以耐受,特别是老年患者化疗更适宜。
Objective: To observe and evaluate the efficacy and toxicity of gemcitabine (GEM) plus vinorelbine (NVB) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: GEM1000mg / m2 plus saline (NS) 100ml, drip within 30 minutes, on the 1st and the first days; NVB25mg / m2 plus NS70ml fast intravenous injection, the first and eighth days. 21 days for a period of at least 2 cycles. RESULTS: Twenty-one NSCLC patients completed 10 cycles of 2 cycles, 6 cycles of 3 cycles, and 5 cycles of 4 cycles of 58 cycles. In CR1, CR1, PR9, SD9 and PD2, the total effective rate (CR + PR) was 47.6%. The initial treatment was in 8 cases and retreatment in 13 cases. The effective rates were 62.5% (5/8) and 38 5 cases (5/13 cases) (P <0.05), 8 cases of squamous cell carcinoma and 13 cases of adenocarcinoma.The effective rates were 62.5% (5/8) and 38.5% (5/13 cases) respectively <0 05). The median survival time (MST) was 11 5 months, and the 1-year survival rate was 42 0%. Toxicity was mainly leukopenia, thrombocytopenia, hemoglobin decreased; leukopenia Ⅲ ~ Ⅳ accounted for 28.6% (6/21), thrombocytopenia and hemoglobin decreased Ⅲ ~ Ⅳ degrees were 14 3% (3/21) and 4.8 % (1/21). Conclusion: Gemcitabine combined with vinorelbine in the treatment of advanced non-small cell lung cancer has a good curative effect and the toxic reaction can be tolerated, especially in elderly patients.